Search Clinical Trials in the European Union
Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1481-1500 of 1,738 trials
Resectable Pancreatic Head Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology
Advanced Non-Squamous Non-Small Cell Lung CancerSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncologyPulmonology
Multiple SclerosisMultiple Sclerosis Spasticity3-6 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesPartially RemoteNeurologyRheumatology
Depression Related to Cancer3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesOncologyPsychiatry
Recalcitrant Lower Limb Nonunion1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOrthopedics and Traumatology
Crohn's Disease>2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine
Non-Small Cell Lung Cancer6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology
Metastatic Pancreatic Cancer6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology
Cystic Fibrosis with Staphylococcus Aureus Infection1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology
Chronic UrticariaEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesAllergologyDermatology
Graves' Ophthalmopathy6-12 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsStandard MedicinesEndocrinologyOphthalmology
High-Risk Soft Tissue Sarcoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyOrthopedics and Traumatology
Moderate-to-Severe Asthma6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementAllergologyPulmonology
Pancreatic Resection>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteGastroenterologyInternal Medicine
ANCA-Associated Vasculitis6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineRheumatology
Stable Ischemic Heart DiseaseEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCardiologyInternal Medicine
Knee Osteoarthritis≤3 monthsSafety phase (I)Efficacy phase (II)Investigational MedicinesInternal MedicineOrthopedics and Traumatology